Journal article
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
- Abstract:
-
Background: Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) through 2 years among patients with PsA in the FUTURE 2 study.
Methods: PASDAS (cut-off scores: remission ≤ 1.9; LDA > 1.9 and < 3.2; Moderate D...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Novartis Pharma
More from this funder
Bibliographic Details
- Publisher:
- BioMed Central Publisher's website
- Journal:
- Arthritis Research and Therapy Journal website
- Volume:
- 20
- Article number:
- 272
- Publication date:
- 2018-12-07
- Acceptance date:
- 2018-11-21
- DOI:
- EISSN:
-
1478-6362
- ISSN:
-
1465-9905
- Source identifiers:
-
945724
Item Description
- Keywords:
- Pubs id:
-
pubs:945724
- UUID:
-
uuid:d4f2b614-25c7-4e5f-ba9f-887cd045df3c
- Local pid:
- pubs:945724
- Deposit date:
- 2018-11-22
Terms of use
- Copyright holder:
- Coates, et al
- Copyright date:
- 2018
- Notes:
- This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record